Previous 10 | Next 10 |
IVERIC bio (NASDAQ:ISEE): Q2 GAAP EPS of -$0.32 misses by $0.06. As of June 30, 2021, the Company had $159.9 million in cash and cash equivalents. Press Release For further details see: IVERIC bio EPS misses by $0.06
- FDA Agreement Under Special Protocol Assessment (SPA) Received for GATHER2 Phase 3 Clinical Trial of Zimura ® in Geographic Atrophy Secondary to Age-Related Macular Degeneration – - Zimura GATHER2 Enrollment Complete; Retention Exceeding Expectations, with In...
IVERIC bio, Inc. (Nasdaq: ISEE) today reported that on August 2, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to five newly hired employees. The inducement grants were approved by the Company’s compensatio...
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its second quarter 2021 financial and operating results on Wednesday, August 4, 2021. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time...
- Topline Data Expected in 2H 2022; if Positive, New Drug Application Expected - IVERIC bio, Inc. (Nasdaq: ISEE) today announced the early completion of patient enrollment of GATHER2, the Company’s second pivotal clinical trial of Zimura ® (avacincaptad p...
Biotech Penny Stocks & Small Caps Gain Ground After Cytokinetics Gets Boost On News When it comes to penny stocks or small-caps, in general, sector & industry trends can play a role. Broader markets and indexes like the S&P 500 ETF ( NYSE: SPY ) and Nasdaq ETF ( NASDAQ...
– Former U.S. Franchise Head of Ophthalmics at Novartis Brings a Proven Track Record in Major Retinal Product Launches – IVERIC bio, Inc. (Nasdaq: ISEE) announced today the appointment of Christopher Simms to Senior Vice President and Chief Commercial O...
Shares of IVERIC bio Inc. (NASDAQ:ISEE) traded today at $10.25, eclipsing its 52-week high. Approximately 1.7 million shares have changed hands today, as compared to an average 30-day volume of 2.5 million shares. In the past 52 weeks, IVERIC bio Inc. share prices are bracketed by a low ...
IVERIC bio (ISEE) has priced its public offering of 11.65M common shares at $8.60/share, for expected gross proceeds of ~$100.2M.Underwriters' over-allotment is an additional ~1.75M shares. Closing date is July 15.Cowen, Credit Suisse and Stifel are acting as the book-running managers fo...
IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock at a price to the public of $8.60 per share, less underwriting discounts and commissions. In addition, in connection wit...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...